Pralsetinib
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Pralsetinib?
Summarize this article for a 10 year old
Pralsetinib, sold under the brand name Gavreto, is a medication approved[10] for RET mutation-positive medullary thyroid cancer (MTC)[11] and RET fusion-positive differentiated thyroid cancer (DTC) refractory to radioactive iodine (RAI) therapy.[12] Pralsetinib is a tyrosine kinase inhibitor. It is taken by mouth.[12]
![]() | |
Clinical data | |
---|---|
Trade names | Gavreto |
Other names | BLU-667 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a620057 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Tyrosine kinase inhibitor |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C27H32FN9O2 |
Molar mass | 533.612 g·mol−1 |
3D model (JSmol) | |
| |
|
The most common adverse reactions include increased aspartate aminotransferase (AST), decreased hemoglobin, decreased lymphocytes, decreased neutrophils, increased alanine aminotransferase (ALT), increased creatinine, increased alkaline phosphatase, fatigue, constipation, musculoskeletal pain, decreased calcium, hypertension, decreased sodium, decreased phosphate, and decreased platelets.[12]
Pralsetinib was approved for medical use in the United States in September 2020,[12][13][14][15][16][excessive citations] and in the European Union in November 2021.[8]